Paul Shilpa, Hagop K and Elias J. (2016): "Adult Acute Lymphoblastic Leukemia." Mayo Clinic Proceedings 91.11 , 1645-666.
2.Sanam Loghavi, Jeffery L. Kutok and Jeffrey L. Jorgensen. (2015): “B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma .” American Journal of Clinical Pathology, vol. 144, no. 3, pp. 393–410., doi:org/10.1309/AJCPAN7BH5DNYWZB.
3.Ustwani, Omar Al , Neha Gupta, Hatoon Bakhribah, Elizabeth Griffith and Eunice Wang, Meir Wetzler. (2016): “Clinical updates in adult acute lymphoblastic leukemia.” Critical Reviews in Oncology/Hematology, vol. 99, 2016, pp. 189–199., doi:10.1016/j.critrevonc.
4.Stams W, Denboer M. and Beverloo H (2005): Expression levels of TEL-AML1 and AML-TEL versus drug sensititvity and clinical outcome in t(21, 21) positive pediatric acute lymphoblastic leukemia. Clin. Cancer Res., 11(8):2974.
5. Satake Noriko,Vikramjit S Kanwar, Jennifer Reikes Willert, Timothy P Cripe and Stephan A Grupp. (2017) ; “Pediatric Acute Lymphoblastic Leukemia.” Practice Essentials, Background, Pathophysiology, emedicine. medscape.com/article/990113-overview.
6. Sallam T, El-Telbany M, Mahmoud H and Iskander M (2013): Significance of Neutopilin-1 Experession in Acute Leukemia. Turk JHaematol. 30: 300-306.
7.Ilana de France, Rui Milton P, Audrey Violeta M, Washington B, Fárida C and Raul A. (2014): “Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia.” Fundac¸ão de Hematologia e Hemoterapia de Pernambuco (HEMOPE), vol. 36, no. 5, 18 July 2014, pp. 351–355., doi:org/10.1016/j.bjhh.2014.07.016.
8.Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M and Peruta B (2009):Improved risk classification for risk-specific therapybased on the molecular study of minimal residual disease(MRD) in adult acute lymphoblastic leukemia (ALL). Blood.2009;113(18):4153–62.
9. Aldoss I, Tracey S, Vinod P, Joycelynne P and Stephen F (2015): “The prognostic significance of additional cytogenetic abnormalities in adults with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplant.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, doi:10.1016/j.clml.2015.04.012.